Clinical Trial Update: An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes [Phase 3]

View source ↗

Summary

An extension study assessing the safety of canakinumab in Japanese patients with periodic fever syndromes was completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Periodic Fever Syndrome

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Periodic Fevers Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2018-08-20